H.R. 5999

H.R. 5999: To amend title 38, United States Code, to direct the Secretary of Veterans Affairs to furnish an opioid antagonist to a veteran without requiring a prescription or copayment.

Reported by Committee Herbert Conaway (D) HOUSE_BILL — 119th Congress
Plain English Summary

H.R. 5999 is a bill that aims to amend existing laws to allow veterans to receive an opioid antagonist, a medication used to reverse opioid overdoses, without the need for a prescription or any copayment. This would make it easier for veterans to access this life-saving treatment.

Positive Media Summary

Many media outlets have praised H.R. 5999 for its proactive approach to addressing the opioid crisis among veterans. Advocates highlight that removing barriers to access for opioid antagonists could significantly reduce overdose deaths in this vulnerable population, emphasizing the importance of timely intervention in emergency situations.

Negative Media Summary

Critics of H.R. 5999 express concerns about the potential for misuse of opioid antagonists if they are made widely available without prescriptions. Some argue that the bill may not address the underlying issues of opioid addiction among veterans and could lead to complacency in seeking comprehensive treatment solutions.

Conflict of Interest Analysis Deep Analysis
0/10
Risk Level
Low
Total Donations
$0
PAC Percentage
0%
Policy Area
Armed Forces and National Security

There are no direct overlaps between the sponsor's top donor industries and the subject matter of the bill. The bill pertains to the provision of opioid antagonists to veterans, which does not directly involve any of the sponsor's top donors. The lobbying activity in this bill's policy area does not indicate any significant financial influence from industries related to the bill's subject matter. While there is lobbying activity from various organizations, none of them are directly related to pharmaceuticals, healthcare, or veterans' affairs. The disclosed amounts from these lobbying activities total $51,000, but again, these are not from industries directly related to the bill's subject matter. Therefore, the risk of conflict of interest is low.

Lobbying Activity — Who's Pushing?

Organizations that lobbied on issues related to this bill's policy area.

Client Lobbying Firm Amount
MARVELL TECHNOLOGY, INC. CLARK STREET ASSOCIATES $30,000
AMERICAN ASSOCIATION FOR JUSTICE LXR GROUP $25,000
BMWED/BRS/SMART-MD/PASSENGER RAIL/NCFOBJ MOONEY, GREEN, SAINDON, MURPHY & WELCH, P.C. $16,000
YELLOWSTONE TO YUKON CONSERVATION INITIATIVE MICHAEL POWELSON $11,000
HEALTHY MARKETS ASSOCIATION LXR GROUP $10,000
UNIAO DA INDUSTRIA DE CANA-DE-AUCAR E BIOENERGIA (UNICA) BARRAL M JORGE CONSULTORES ASSOCIADOS LTDA $10,000
CONFEDERACAO NACIONAL DAS INSTITUICOES FINANCEIRAS BARRAL M JORGE CONSULTORES ASSOCIADOS LTDA $10,000
NATL ASSC OF STATE DIRECTORS OF CAREER TECHNICAL EDUCATION NATL ASSC OF STATE DIRECTORS OF CAREER TECHNICAL EDUCATION undisclosed
BRAZILIAN AVOCADO COMMISSION FEDERAL STRATEGIES GROUP, INC. undisclosed
SAAGA FEDERAL STRATEGIES GROUP, INC. undisclosed
UNIVERSITY AT BUFFALO STATE UNIVERSITY OF NEW YORK AT BUFFALO undisclosed
THE GREAT PLAINS INSTITUTE FOR SUSTAINABLE DEVELOPMENT, INC. KOUNTOUPES DENHAM CARR & REID, LLC undisclosed
CLOUDTRUCKS INVARIANT LLC undisclosed
LOS ANGELES CLEANTECH INCUBATOR INVARIANT LLC undisclosed
THE SCIENCE COALITION FORBES-TATE undisclosed

Source: Senate Lobbying Disclosure Act (LDA) filings, 2026

TheBillRoom is free and independent. No ads, no subscriptions, no political funding. If this analysis was useful, reader support keeps it running.
Support Us